Five Prime Therapeutics

Five Prime Therapeutics Newswire

Comprehensive Real-Time News Feed for Five Prime Therapeutics.

Results 1 - 20 of 93 in Five Prime Therapeutics

  1. The Global Deflationary TsunamiRead the original story w/Photo

    Friday Mar 20 | Daily Kos

    Every few years an economic event will happen that can be easily seen by everyone except mainstream economists. Today that economic event is a global tidalwave of deflation that is sweeping the globe.

    Comment?

  2. Five Prime Therapeutics, Inc. Announces Fourth Quarter And Full Year 2014 Financial ResultRead the original story

    Tuesday Mar 17 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2014. "2014 was a remarkable year for Five Prime," said Lewis T. "Rusty" Williams, M.D., Ph.D., Founder and Chief Executive Officer of Five Prime.

    Comment?

  3. Five Prime Therapeutics Announces Fourth Quarter and Full Year 2014 Financial ResultsRead the original story w/Photo

    Tuesday Mar 17 | GlobeNewswire

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2014. "2014 was a remarkable year for Five Prime," said Lewis T. "Rusty" Williams, M.D., Ph.D., Founder and Chief Executive Officer of Five Prime.

    Comment?

  4. Five Prime Therapeutics, Inc. To Announce Fourth Quarter And Full...Read the original story

    Tuesday Mar 10 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its fourth quarter and full year 2014 financial results on Tuesday, March 17, 2015, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Tuesday, March 17, 2015 at 5:00 p.m. /2:00 p.m. to discuss the company's financial results and provide a general business update.

    Comment?

  5. Five Prime Therapeutics, Inc. To Present At The Global Healthcare ConferenceRead the original story

    Thursday Mar 5 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Julie Hambleton, M.D., Chief Medical Officer, will present at the Barclays Global Healthcare Conference on Thursday, March 12, 2015 at 1:05 PM Eastern Daylight Time. The conference will take place at the Loews Miami Beach Hotel.

    Comment?

  6. Three Reasons Why The Bay Area Beats Other Biotech HubsRead the original story

    Feb 24, 2015 | BioSpace

    BayBio, the longtime Northern California life sciences trade group, is in the final days before it merges with the California Healthcare Institute to give the biotech industry a bigger voice in Sacramento and Washington, D.C. But Gail Maderis, who shepherded the organization for more than five years after stepping down as CEO of Five Prime Therapeutics Inc., isn't backing down. With a figurative foam "We're #1" finger on her hand, in her final letter to BayBio members, Maderis shuns the "Top 10" lists and outlines why the Bay Area beats other regional biotech hubs.

    Comment?

  7. BayBio boss' goodbye: 3 reasons why the Bay Area beats other biotech hubsRead the original story w/Photo

    Feb 24, 2015 | Business Journal

    BayBio, the longtime Northern California life sciences trade group, is in the final days before it merges with the California Healthcare Institute to give the biotech industry a bigger voice in Sacramento and Washington, D.C. But Gail Maderis, who shepherded the organization for more than five years after stepping down as CEO of Five Prime Therapeutics Inc., isn't backing down. With a figurative foam "We're #1" finger on her hand, in her final letter to BayBio members , Maderis shuns the "Top 10" lists and outlines why the Bay Area beats other regional biotech hubs.

    Comment?

  8. Scientists unveil map of 'epigenome,' a second genetic codeRead the original story w/Photo

    Feb 18, 2015 | CNews

    Scientists for the first time have mapped out the molecular "switches" that can turn on or silence individual genes in the DNA in more than 100 types of human cells, an accomplishment that reveals the complexity of genetic information and the challenges of interpreting it. Researchers unveiled the map of the "epigenome" in the journal Nature on Wednesday, alongside nearly two dozen related papers.

    Comment?

  9. Beyond DNA: 'Second genetic code' that turns genes on and off mappedRead the original story w/Photo

    Feb 18, 2015 | CBC News

    Linda Lewis, right, and Leora Eisen are identical twins who were featured in the documentary Two of a Kind, which examines the differences between identical twins. Many of those differences are due to the epigenome, a "second genetic code" of switches that turn genes on and off.

    Comment?

  10. Scientists Unveil Map of 'Epigenome,' a 2nd Genetic CodeRead the original story w/Photo

    Feb 14, 2015 | Voice of America

    A DNA double helix is seen in an undated artist's illustration released by the National Human Genome Research Institute. FILE - A DNA double helix is seen in an undated artist's illustration released by the National Human Genome Research Institute.

    Comment?

  11. Five Prime Therapeutics, Inc. To Present At The 2015 Global Healthcare ConferenceRead the original story

    Feb 4, 2015 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015 at 8:25 AM Eastern Standard Time. The conference will take place at the Waldorf Astoria Hotel in New York City.

    Comment?

  12. 5 Things Bristol-Myers Squibb Co.'s Management Wants You to KnowRead the original story w/Photo

    Feb 4, 2015 | The Motley Fool

    ... has been busy signing numerous research deals with partners including Celgene , Novartis , and Five Prime Therapeutics to bolster its immuno-oncology platform. This trend appears set to continue going forward. This coming blockbuster will make every

    Comment?

  13. Roche Says Swiss Franc's Surge May Erode Profit Growth This YearRead the original story

    Jan 28, 2015 | The Washington Post

    Roche Holding AG, the world's largest seller of cancer drugs, said the Swiss franc's surge may strip 9 percentage points from growth in operating profit this year. The currency's strength will probably pare 6 percentage points from sales growth, based on the average exchange rate for January, Chief Financial Officer Alan Hippe said at a press conference in Basel today.

    Comment?

  14. Roche Sees Profit, Sales IncreasingRead the original story w/Photo

    Jan 28, 2015 | Wall Street Journal

    Roche Holding AG posted a 16% drop in annual profit as the Swiss drug maker booked large impairments and restructured its debt, but the company said Wednesday it expects sales and profit to increase this year. Basel-based Roche said sales are expected to grow in low- to mid-single digits in 2015, when stripping out the effect of foreign-currency exchange rate fluctuations.

    Comment?

  15. Apple's Earnings Report Looks Optimistic: MunsterRead the original story w/Photo

    Jan 27, 2015 | Bloomberg

    Jan. 27 -- Piper Jaffray's Gene Munster discusses Apple's fiscal first-quarter profit with Bloomberg's Cory Johnson on "Bloomberg West." Jan. 28 -- Cancer drug Kadcyla "will remain a very important growth driver," said Roche Holding AG Chief Executive Officer Severin Schwan in an interview with Manus Cranny on Bloomberg Television's "Countdown" from Basel.

    Comment?

  16. Roche misses forecasts as costs riseRead the original story w/Photo

    Jan 27, 2015 | MarketWatch

    Swiss drug maker Roche Holding AG said Wednesday that its full-year net income fell 16% despite rising sales of its cancer treatments. Basel-based Roche said net income attributable to shareholders fell to 9.33 billion Swiss francs from 11.16 billion francs a year earlier, missing analysts' forecasts of 11.54 billion francs.

    Comment?

  17. Roche Profit Misses ForecastsRead the original story w/Photo

    Jan 27, 2015 | Wall Street Journal

    Swiss drug maker Roche Holding AG said Wednesday that its full-year net income fell 16% despite rising sales of its cancer treatments. Basel-based Roche said net income attributable to shareholders fell to 9.33 billion Swiss francs from 11.16 billion francs a year earlier, missing analysts' forecasts of 11.54 billion francs.

    Comment?

  18. Zeltiq Aesthetics Inc (ZLTQ), Five Prime Therapeutics Inc (FPRX): Point72's Latest Bullish MovesRead the original story w/Photo

    Jan 27, 2015 | Insider Monkey

    Steve Cohen 's Point72 Asset Management has made bullish moves into a pair of medical technology stocks. According to separate filings with the SEC, the fund has obtained 5.2% and 5.0% stakes in Zeltiq Aesthetics Inc and Five Prime Therapeutics Inc , respectively.

    Comment?

  19. Justin Sullivan/Getty Images For a few holdouts, Mass. still isn't biotech centerRead the original story w/Photo

    Jan 19, 2015 | Boston.com

    Genetech, headquartered in south San Francisco, does not plan to open a research and development facility in the Boston area. "We do deals with Boston companies.

    Comment?

  20. Jefferies Group Raises Five Prime Therapeutics Price Target to $32.00Read the original story

    Jan 16, 2015 | AmericanBankingNews.com

    ... analysts have also recently issued reports about the stock. Analysts at Zacks upgraded shares of Five Prime Therapeutics from a "neutral" rating to an "outperform" rating and set a $29.50 price target on the stock in a research note on Tuesday. ...

    Comment?